A B S T R A C T Herpes zoster (HZ) can have a substantial impact on quality of life (QoL). The vaccine efficacy (VE) of a recombinant zoster vaccine (RZV) was 68.2% (95% confidence interval [CI], 55.6% to 77.5%) in a phase 3 study in adult autologous hematopoietic stem cell transplant (HSCT) recipients (NCT01610414). Herein, we report the impact of RZV on patients' QoL. Autologous HSCT recipients were randomized 1:1 to receive 2 doses of RZV or placebo, given 1 to 2 months apart. QoL was measured by the Short Form Survey-36 and Euro-QoL-5 Dimension at baseline, 1 month, and 1 year postdose 2 and during suspected HZ episodes with the Zoster Brief Pain Inventory (ZBPI). The RZV impact journal homepage : www.bbmt.org on ZBPI burden of illness and burden of interference scores was estimated. The 2 scores were calculated from the area under the curve (days 0 to 182) of the ZBPI worst pain and ZBPI activities of daily living scores, respectively, assuming a score of 0 for patients not having a confirmed HZ episode. The ZBPI maximum worst pain score was significantly lower in the RZV than placebo group (mean: 5.8 versus 7.1, P = .011). Consequently, the VE estimates for HZ burden of illness (82.5%; 95% CI, 73.6 to 91.4) and burden of interference (82.8%; 95% CI, 73.3 to 92.3) were higher than the HZ VE estimate (ie, 68.2%). RZV showed significantly better QoL scores than placebo 1 week following rash onset among patients with confirmed HZ. In addition to reducing the risk of HZ and its complications, RZV significantly reduced the impact of HZ on patients' QoL in those who developed breakthrough disease.
INTRODUCTION
Herpes zoster (HZ), which occurs following the reactivation of latent varicella zoster virus (VZV), usually presents as a painful vesicular dermatomal rash [1, 2] . VZV cell-mediated immunity, which inhibits the development of HZ, can decline for a number of reasons, including increasing age and immune suppression [3, 4] . Patients with malignant, chronic, or autoimmune conditions, or those receiving immunosuppressive therapies, therefore have an increased risk of developing HZ [5] . Hematopoietic stem cell transplantation is the risk factor with the highest odds ratio for developing HZ (odds ratio, 13.46) [5] . Several studies reported an increased risk of HZ among stem cell transplant recipients, with incidence rates reaching 41.7 per 1000 person years [6] [7] [8] [9] [10] .
In addition to the increased risk of HZ in patients with various immunocompromising conditions, these individuals also experience an increased severity of disease. For example, high proportions of hematopoietic stem cell transplant (HSCT) recipients develop complications, including postherpetic neuralgia following HZ [11, 12] .
In a study in Canada, Drolet et al. [13] reported that individuals with an impaired immune status had HZ severity of illness scores, as measured by the Zoster Brief Pain Inventory (ZBPI), that were twice as high as individuals with normal immune function. In a study in the United States, Yawn et al. [14] reported that although 8% of HZ cases occurred among immunocompromised patients, these individuals represented 23.8% of the total HZrelated costs. Another study, based on data from the United Kingdom, demonstrated that the highest direct medical costs related to patients with HZ were observed in HSCT recipients [15] .
Prevention of HZ in HSCT recipients is traditionally achieved using oral acyclovir or valacyclovir. However, as there is still a high risk of HZ once treatment is stopped, the optimal duration of prophylaxis remains unclear [8, 16, 17] . A live-attenuated vaccine produced by Merck (Zostavax, New Jersey, United States) is licensed to prevent HZ in immunocompetent adults aged 50 years. However, the vaccine is contraindicated in immunocompromised individuals, in whom administration may result in disseminated disease. Recently, a nonlive 2-dose adjuvanted recombinant zoster vaccine (RZV) produced by GlaxoSmithKline (Shingrix, United Kingdom) was licensed in adults aged 50 years [18] . This vaccine consists of the VZV glycoprotein E antigen and an adjuvant system (AS01 B ). The vaccine efficacy (VE) in preventing HZ in immunocompetent individuals was 97.2% in adults 50 years and 91.3% in older adults 70 years [19, 20] .
This phase III ZOster Efficacy trial in HSCT recipients (NCT01610414; ZOE-HSCT) was designed to explore the impact of RZV (2 doses administered 1 to 2 months apart starting 50 to 70 days post-transplantation) on reducing the burden of HZ in autologous HSCT recipients. The efficacy, safety, and immunogenicity results of the study are published elsewhere [21] ; only the quality-of-life (QoL) results are presented here. The VE of RZV in preventing HZ in adult autologous HSCT recipients was 68.2% (95% confidence interval [CI], 55.6% to 77.5%). In this article, we present further results from the ZOE-HSCT trial concerning the impact of RZV on the burden of HZ illness, the burden of HZ interference on patients' activities of daily living (ADLs), and the effect of HZ on patients' QoL.
MATERIALS AND METHODS
This randomized, placebo-controlled, phase III multicenter study assessed the efficacy, immunogenicity, and safety of RZV in autologous HSCT recipients aged 18 years. The study design has been described in detail in the study presenting the efficacy and safety results of the trial [21] .
Outcome Measures
The ZBPI questionnaire asks the participant to rate 4 categories of pain (least, worst, and average "in the last 24 hours," in addition to "right now") on 11-point Likert-type scales (0 to 10, with 10 signifying the worst imaginable pain). The ZBPI also assesses the degree to which HZ pain interfered with 7 ADLs: general activity, mood, walking ability, work, relation with others, sleep, and enjoyment of life. These were all rated on 11-point Likert-type scales, with 0 signifying "does not interfere" and 10 "completely interferes." A summary ADL score was calculated by averaging the scores for all 7 activities.
Autologous HSCT recipients with suspected HZ were asked to complete the ZBPI at home every day from rash onset until the first visit to the site. They completed a ZBPI on site at this visit, at home for the next 28 days, and weekly thereafter until either they had been pain free for 4 consecutive weeks or 90 days had elapsed since the onset of the rash (whichever came last). For all analyses of data involving HZ episodes, day 0 was defined as the first day of HZ rash [22] .
EuroQol-5 Dimension (EQ-5D) is a utility instrument widely used to assess individuals' health-related QoL. Autologous HSCT recipients were asked to grade the extent of their problems (no problem, some problems, and severe problems) in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The combination of answers to the 5 dimensions results in 243 possible health states, each of which could be translated into a utility score ranging from below 0 (a health state worse than death) to 1 (best possible health state) [23] . QoL was also assessed using the Short Form Survey-36 (SF-36) [24] . The SF-36 is a self-reported multidimensional instrument designed to assess overall health status and QoL. It consists of 36 questions covering 8 domains: physical function, physical role, general health, bodily pain, mental health, social functioning, vitality/fatigue, and emotional role. Responses from these domains are subsequently summarized into 2 component scores: physical and mental.
All autologous HSCT recipients completed the EQ-5D and SF-36 questionnaires at baseline (ie, before vaccination dose 1). Autologous HSCT recipients who did not develop HZ also completed the questionnaires at 1 month and 1 year postvaccination, whereas all those experiencing a suspected HZ episode completed both the EQ-5D and SF-36 weekly during the entire period that the ZBPI questionnaires were completed.
Statistical Analyses
For each case of HZ, the maximal ZBPI worst and average pain scores during the HZ episode were calculated and compared between the RZV and placebo groups by means of the Wilcoxon nonparametric test. Clinically significant pain was defined as a ZBPI worst pain score greater than or equal to 3.
The ZBPI severity of illness scores were calculated as the area under the curve (AUC) of the ZBPI worst pain score from day 0 until day 182 [22] . A ZBPI severity of illness score of 0 was imputed for autologous HSCT recipients without confirmed HZ. The burden of illness due to pain was then estimated by aggregating the severity of illness scores over all the autologous HSCT recipients in a group and dividing by the total number of years of participant follow-up. Consequently, this composite measure took into account the incidence of HZ as well as the severity and duration of HZ pain.
VE was defined as the relative reduction in the burden of illness score in the RZV group compared with the score in the placebo group and calculated as 1 minus the relative risk (ie, the burden of illness score in the RZV group divided by the burden of illness score in the placebo group). The VE in reducing the burden of interference was defined and calculated in a similar way using the composite ZBPI ADL score as the measure.
These analyses were performed on the modified Total Vaccinated Cohort (mTVC), which excluded autologous HSCT recipients who did not receive 2 doses or who had a confirmed HZ episode within 1 month of receiving dose 2, and included only patients with HZ who completed at least 1 ZBPI questionnaire. The Chop-Lump [25] test was used to assess the difference in ZBPI severity of illness scores and ZBPI severity of interference scores between the RZV and placebo groups in the mTVC cohort.
The VE for reducing severe ZBPI pain (score 7 for worst pain) was estimated in the ZBPI evaluable subgroup, which comprised autologous HSCT recipients in the mTVC with confirmed HZ cases who had completed a ZBPI questionnaire during the first 14 days after HZ onset. Standardized asymptotic binomial CIs for the VE were calculated using the score method of Farrington and Manning [26] .
A repeated-measures analysis of variance model (ANOVA) was fitted including terms for region, age, sex, and a vaccine-by-time (window) interaction [27] .
The least squares mean estimates for time by vaccine effects were obtained from the ANOVA model. The associated differences in least squares means and P values were also estimated. A multivariate rank analysis of repeated-measures ordinal categorical data was carried out using the Wei-Lachin method, which assumes that missing data are missing at random [28] . A repeated-measures ANOVA model was fitted to estimate the impact of HZ on EQ-5D utility scores in the placebo group only, stratified by age. The model included the baseline utility scores (ie, the most recent utility assessment before the onset of HZ and the utility scores during the first 4 weeks of the HZ episode).
RESULTS
Most participants in the TVC were white (78.4%), male (62.7%), and aged 50 years (75.1%). At a median follow-up of 21 months, 49 confirmed HZ cases had occurred among the 870 autologous HSCT recipients receiving RZV compared with 135 among the 851 receiving placebo in the mTVC (Figure 1 ). Figure 1 . Flowchart for the ZOE-HSCT study. mTVC: excluded autologous HSCT recipients who did not receive 2 doses of RZV or who had a confirmed HZ episode within 1 month of receiving dose 2. mTVC ZBPI evaluable HZ cases: included HZ confirmed cases in participants who completed a ZBPI questionnaire within 14 days postrash onset.
The demographic data of the autologous HSCT recipients who developed confirmed HZ are presented Table 1 . The mean ages of both groups were similar, but there were proportionally more males and more whites in the RZV group.
The mean time between the onset of rash and first HZ evaluation was 2.8 (range, 0 to 16) and 3.4 (range, 0 to 29) days in the RZV and placebo groups, respectively. Completion rates for the ZBPI questionnaire were approximately 40% on day 0, >60% from day 3 onward, and 80% from day 6 onward. The mTVC HZ confirmed caseÀZBPI evaluable subgroup, comprised 44 RZV and 125 placebo autologous HSCT recipients. The completion rate of the EQ-5D and SF-36 instruments during an ongoing HZ episode was approximately 50% on day 0 and 77% at all time points thereafter.
ZBPI Figure 2 displays the mean ZBPI worst pain scores ( Figure 2A ) and ADL scores ( Figure 2B ) per day during the first 28 days after rash onset for the mTVC HZ confirmed caseÀZBPI evaluable subgroup. The mean ZBPI worst pain and ADL scores were lower in the RZV group than in the placebo group at all time points (overall Wei-Lachin test P = .003 and P = .012, respectively). This observation was relatively consistent for all of the ZBPI ADL individual items (ie, ZBPI general activity score: P = .009, ZBPI mood score: P = .067, ZBPI walking ability score: P = .002, ZBPI normal work score: P = .003, ZBPI relations score: P = .022, ZBPI sleep score: P = .018, ZBPI enjoyment of life score: P = .046, data not shown). Table 2 presents the distribution of the individual maximal ZBPI worst pain and average pain scores experienced over the entire HZ episode. A severe ZBPI worst pain score (ie, 7) was reported by 47.7% of the RZV group and 68.8% of placebo HZ cases (VE, 30.6%; 95% CI, 6.7% to 51.8%). The corresponding proportions reporting severe average pain were 22.7% and 44.0%, respectively (VE, 48.4%; 95% CI, 11.9% to 71.7%). The median time to resolution of clinically significant pain was 20 days in the RZV group and 31 days in the placebo group (P = .048). Table 3 presents the mean AUC for the ZBPI worst pain and ADL scores. For all time periods, the AUC of the ZBPI worst pain score was statistically significantly lower in the RZV group compared with placebo (P .004). Similarly, the AUC of the ZBPI ADL scores was statistically significantly lower in the RZV group compared with placebo (P .014 for all time periods). 
SF-36 and EQ-5D
The QoL scores by SF-36 tended to be higher in the RZV group compared with placebo. For example, at week 1 post HZ rash onset, when the greatest differences were observed, statistically significant differences in favor of RZV (P < .05) were observed for the SF-36 bodily pain, social functioning, role emotional, mental health, and mental component scores ( Table 4 ).
The estimated mean EQ-5D utility scores over time are shown in Figure 3 . The differences between RZV and placebo groups were greatest at week 1 and decreased over time. At week 1, the EQ-5D utility score was significantly higher in the RZV group compared with placebo (P = .0021).
The estimated utility loss of autologous HSCT recipients in the placebo group, who developed HZ over the first 28 days after rash onset, is presented by age (ie, 18 to 49 and 50 years) in Table 5 . The utility loss was highest on day 0 and decreased over time in both age groups as the autologous HSCT recipients recovered from HZ. Nevertheless, a negative impact of HZ on QoL remained until the end of week 4.
Vaccine Efficacy
As seen in Table 6 , the overall VE estimate for the burden of illness score was 82.5% (95% CI, 73.6% to 91.4%) with point estimates of 83.4 and 82.4 in the 18 to 49 and 50 years age groups, respectively. The overall VE estimate for the burden of interference score was 82.8% (95% CI, 73.3% to 92.3%) with point estimates of 79.6 and 83.6 in the 18 to 49 and 50 years age groups, respectively. . Estimated mean EQ-5D utility scores during the first 28 days after rash onset (mTVC HZ confirmed cases). An EQ-5D value of 1 represents the best possible health state. Diff (CI), difference (CI).
DISCUSSION
Recipients of HSCT have both an increased incidence and severity of HZ [5] [6] [7] 11, 12] . In this trial, the overall efficacy of RZV in preventing HZ cases in autologous HSCT recipients was 68.2% (95% CI, 55.6% to 77.5%) [21] . In this article, it was further demonstrated that even when RZV failed to prevent HZ, vaccine recipients experienced less severe pain, had a shorter duration of pain, had less interference in ADLs, and had higher QoL scores compared with the placebo group. Therefore, RZV not only prevented HZ but also attenuated the severity of disease in RZV recipients who developed HZ during this study. Consequently, the overall efficacy of RZV in reducing the burden of illness of HZ and the burden of interference in ADLs exceeded 80%.
In the preceding ZOE-50 study and ZOE-70 pooled analysis, in older adults, only 9 of 7340 and 25 of 7413 participants developed HZ in the RZV groups, respectively, compared with 49 of 870 HSCT recipients in the current study [19] [20] [21] . The magnitude of differences in pain scores, between the RZV and placebo groups, in this present study during the acute HZ period was consistent with the ZOE-50 and the ZOE-70 pooled analysis. However, due to more individuals developing breakthrough HZ in the ZOE-HSCT study, the statistical power to detect significant differences between the groups was higher in the present study.
Although the ZBPI pain scores in the placebo group in ZOE-50, ZOE-70 pooled analysis, and ZOE-HSCT studies appeared to be similar during the first week following rash onset, there were differences in the median time to resolution of clinically significant pain (17, 22 , and 31 days, respectively). The HZ burden of illness scores in the placebo group of the ZOE-50 and ZOE-70 pooled analysis were approximately 1.2 and 1.7, respectively [29] , compared with 16.9 in the ZOE-HSCT study. As such, the HZ burden of illness is of a magnitude of approximately 10 times higher in autologous HSCT recipients, due to a combination of both a higher incidence and a greater severity of disease. Consequently, although the RZV VE is lower in autologous HSCT recipients compared with healthy individuals receiving RZV, the absolute reduction of HZ burden of illness is meaningfully higher in autologous HSCT recipients.
Interestingly, in the placebo group of this study, the HZ burden of illness and HZ burden of interference scores were lower in younger rather than older autologous HSCT recipients (Table 5) ; however, the utility losses appeared to be greater in younger compared with older autologous HSCT recipients ( Table 4 ). As such, the reduction in HZ-related burden appears important for both the young and older autologous HSCT recipients.
The vaccine efficacy reported in this study was similar to that of a heat-inactivated varicella-zoster virus vaccine administered to a similar HSCT population [30] . However, the latter was achieved using a 4-dose schedule of the heat-inactivated vaccine compared with a 2-dose schedule of RZV. Furthermore, the first dose of the 4-dose regimen was administered 1 month before autologous HSCT, which can be logistically challenging [21] .
This study has some limitations. The QoL endpoints were either secondary or exploratory endpoints within the ZOE-HSCT study, and as such, the study was not powered to show specific differences in QoL parameters between the RZV and placebo groups. Similarly, the study was not stratified or powered to draw conclusions by age groups.
This study of autologous HSCT recipients demonstrates that RZV reduces both the frequency and severity of HZ. The HZ burden of illness is dramatically higher in autologous HSCT recipients compared with healthier individuals included in the prior ZOE studies. The results from this transplant study support the findings from the previous ZOE studies in older adults and An EQ-5D value of 1 represents the best possible health state. * P value is based on the repeated-measures mixed-effects model testing the null hypothesis that the utility loss = 0. Three and 2 participants in the RZV and placebo groups, respectively, had a confirmed HZ episode but did not have an evaluable ZBPI score and were therefore not included in this table. The ZBPI severity of illness and severity of interference scores were calculated as the AUC, days 0 to 182, of the ZBPI worst pain scores and ZBPI Activities of daily living scores, respectively, for participants with confirmed HZ cases. Participants without a confirmed HZ case were allocated an AUC score of 0. The ZBPI burden of illness and burden of interference scores were calculated as the sum of the ZBPI severity of illness and severity of interference scores, respectively, and divided by the total follow-up in years. Higher scores represent more burden. m indicates number of HZ cases in each vaccination group.
suggest that the RZV vaccine, in addition to being efficacious in preventing HZ, has a benefit in attenuating the severity of HZ disease in breakthrough cases, including in transplant recipients younger than 50 years of age. In conclusion, RZV may represent an additional prophylactic intervention in the care of patients after autologous HSCT, who are at high risk for HZ.
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